Endothelial function in the forearm circulation of patients with the metabolic syndrome effect of different lipid-lowering regimens

被引:39
作者
Bulut, D [1 ]
Hanefeld, C [1 ]
Bulut-Streich, N [1 ]
Graf, C [1 ]
Mügge, A [1 ]
Spiecker, M [1 ]
机构
[1] Univ Bochum, St Josef Hosp, Dept Med 2, Heart & Vasc Ctr, DE-44791 Bochum, Germany
关键词
dyslipidemia; endothelial function; ezetimibe; forearm blood flow; metabolic syndrome; statin therapy;
D O I
10.1159/000088105
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We compared the effect of statin therapy (either alone or combined with ezetimibe) on the inhibition of cholesterol resorption and endothelial function by measuring forearm blood flow in male patients with the metabolic syndrome. Compared to 40 mg atorvastatin alone, combination therapy with 10 mg ezetimibe and 10 mg atorvastatin for 8 weeks resulted in signifi cantly decreased total serum cholesterol and triglycerides levels (n = 14). Endothelium-dependent, acetylcholine- mediated vasodilation was signifi cantly better with combination therapy (p < 0.05). In contrast, endothelium- independent forearm blood flow response to sodium nitroprusside was comparable in both groups. Our data suggest a more effective restoration of endothelial function with the statin/ezetimibe combination compared to statin monotherapy in patients with the metabolic syndrome.
引用
收藏
页码:176 / 180
页数:5
相关论文
共 18 条
[1]   Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia - A prospective, randomized, double-blind trial [J].
Ballantyne, CM ;
Houri, J ;
Notarbartolo, A ;
Melani, L ;
Lipka, LJ ;
Suresh, R ;
Sun, S ;
LeBeaut, AP ;
Sager, PT ;
Veltri, EP .
CIRCULATION, 2003, 107 (19) :2409-2415
[2]   Impaired vasodilator responses to atrial natriuretic peptide in essential hypertension [J].
Bulut, D ;
Potthast, R ;
Hanefeld, C ;
Schulz, T ;
Kuhn, M ;
Mügge, A .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 (07) :567-573
[3]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[4]   Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome [J].
Cottrell, DA ;
Marshall, BJ ;
Falko, JM .
CURRENT OPINION IN CARDIOLOGY, 2003, 18 (04) :301-308
[5]   REGULATION OF THE MEVALONATE PATHWAY [J].
GOLDSTEIN, JL ;
BROWN, MS .
NATURE, 1990, 343 (6257) :425-430
[6]   Specific impairment of endothelium-dependent vasodilation in subjects with type 2 diabetes independent of obesity [J].
Hogikyan, RV ;
Galecki, AT ;
Pitt, B ;
Halter, JB ;
Greene, DA ;
Supiano, MA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (06) :1946-1952
[7]   The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men [J].
Lakka, HM ;
Laaksonen, DE ;
Lakka, TA ;
Niskanen, LK ;
Kumpusalo, E ;
Tuomilehto, J ;
Salonen, JT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (21) :2709-2716
[8]  
Laufs U, 2000, CIRCULATION, V102, P3104
[9]   Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men [J].
Laufs, U ;
Wassmann, S ;
Hilgers, S ;
Ribaudo, N ;
Böhm, M ;
Nickenig, G .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (11) :1306-+
[10]   Current perspectives on statins [J].
Maron, DJ ;
Fazio, S ;
Linton, MF .
CIRCULATION, 2000, 101 (02) :207-213